EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimized GENE TARGET framework characterizes barriers to therapeutic development for monogenic neurodevelopmental disorders

Raymond Belanger Deloge, Abigail Sveden, Zoë Frazier, Hailey Osika, Charlotte Byrne, Jillian O'Toole, Muhammed Bayraktutan, Kira A Dies, Stephanie J Brewster, Pilar Trelles, Morgan E Ryan, Bo Zhang und 7 weitere

Molecular Therapy Advances · 2026-12 · 34 (4) · 201871

DOI: 10.1016/j.omta.2026.201871 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Raymond Belanger Deloge und 18 weiteren Autor:innen. Beteiligte Einrichtung: Rosamund Stone Zander and Hansjoerg Wyss Translational Neuroscience Center, Boston Children's Hospital, Boston, MA 02115, USA. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GENE TARGET is a previously published framework designed to quantitatively assess the suitability of a specific monogenic neurodevelopment disorder (NDD) for development of genetic therapies, addressing the need for a systematic and rigorous approach to research prioritization and resource allocation. Here, to keep pace with the rapidly evolving knowledgebase, we refined the framework with more nuanced scoring definitions and added a resource guide to standardize evaluation of each criterion. Interrater agreement was assessed and found to be substantial for most domain/criteria scores among experienced users, primarily genetic counselors with at least two years of experience in translational genomic medicine. Secondary scoring adjudication by experts with clinical/molecular genetics and preclinical modeling expertise is recommended. Cross-disorder analysis of 57 NDD gene-disorder pairs evaluated at the Translational Neuroscience Center was performed, which identified clinical considerations, including establishing endpoints, as the most common translational research gap. Common barriers across disorders also included generating natural history data, establishing an early diagnosis, understanding dosage sensitivity, and demonstrating phenotypic reversibility. We further discuss application of this framework for gene editing and small molecules approaches. Future goals include the validation of GENE TARGET beyond academic research settings and the use of artificial intelligence to aid in preliminary scoring.

Schlagwörter

Stichwörter der Autor:innen

antisense oligonucleotidesbioethicsbrain deliveryclinical trial readinessgene dosagegene editinggene therapyneurodevelopmental disordersrare diseasestranslational research

Autor:innen und Institutionen

  • Rosamund Stone Zander and Hansjoerg Wyss Translational Neuroscience Center, Boston Children's Hospital, Boston, MA 02115, USA.
  • Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • MGH Institute of Health Professions, Boston, MA, USA.
  • Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Psychiatry and Behavioral Sciences, Boston Children's Hospital, Boston, MA, USA.
  • Biostatistics and Research Design Center, Institutional Centers for Clinical & Translational Research, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Förderung

  • NICHD NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Belanger Deloge, R., Sveden, A., Frazier, Z., Osika, H., Byrne, C., O'Toole, J., Bayraktutan, M., Dies, K. A., Brewster, S. J., Trelles, P., Ryan, M. E., Zhang, B., Prock, L., Hubbs, J., Buttermore, E. D., Chung, W. K., Thurm, A., Sahin, M., & Chopra, M. (2026). Optimized GENE TARGET framework characterizes barriers to therapeutic development for monogenic neurodevelopmental disorders. Molecular Therapy Advances, 34(4), 201871. https://doi.org/10.1016/j.omta.2026.201871

Vancouver

Belanger Deloge R, Sveden A, Frazier Z, Osika H, Byrne C, O'Toole J, et al. Optimized GENE TARGET framework characterizes barriers to therapeutic development for monogenic neurodevelopmental disorders. Molecular Therapy Advances. 2026;34(4):201871. doi:10.1016/j.omta.2026.201871

BibTeX
@article{BelangerDeloge2026,
  author = {Belanger Deloge, Raymond and Sveden, Abigail and Frazier, Zoë and Osika, Hailey and Byrne, Charlotte and O'Toole, Jillian and Bayraktutan, Muhammed and Dies, Kira A and Brewster, Stephanie J and Trelles, Pilar and Ryan, Morgan E and Zhang, Bo and Prock, Lisa and Hubbs, Jed and Buttermore, Elizabeth D and Chung, Wendy K and Thurm, Audrey and Sahin, Mustafa and Chopra, Maya},
  title = {Optimized GENE TARGET framework characterizes barriers to therapeutic development for monogenic neurodevelopmental disorders},
  journal = {Molecular Therapy Advances},
  year = {2026},
  volume = {34},
  number = {4},
  pages = {201871},
  doi = {10.1016/j.omta.2026.201871}
}
Kostenlos starten →